Search Results for "Oseni"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Oseni. Results 1 to 2 of 2 total matches.
See also: alogliptin, pioglitazone
Alogliptin (Nesina) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 27, 2013 (Issue 1417)
/pioglitazone (Oseni) for the same indication.
Alogliptin is the fourth DPP-4 inhibitor to become available ...
The FDA has approved the dipeptidyl peptidase-4
(DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment
of type 2 diabetes. In addition to the single-ingredient
product, the FDA also approved fixed-dose
combinations of alogliptin/metformin (Kazano) and
alogliptin/pioglitazone (Oseni) for the same indication.
Alogliptin is the fourth DPP-4 inhibitor to become available
in the US. The other three – saxagliptin (Onglyza),
sitagliptin (Januvia), and linagliptin (Tradjenta) – are also
available in fixed-dose combinations with metformin.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
/pioglitazone – generic 12.5/15, 12.5/30, 12.5/45, 25/15-25/45 mg PO once/day12,32,33,41 195.00
Oseni (Takeda ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.